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Background: There are a number of instruments that describe severity and progression of multiple sclerosis and
they are increasingly used as endpoints to assess the effectiveness of therapeutic interventions. We examined to
what extent the psychometric properties of two accepted instruments – EDSS and MSFC – meet methodological
standards and the value they have in clinical trials.
Methods: We conducted a systematic literature search in relevant databases [MEDLINE (PubMed), ISI Web of
Science, EMBASE, PsycINFO & PSYNDEX, CINAHL] yielding 3,860 results. Relevant full-text publications were identified
using abstract and then full-text reviews, and the literature was reviewed.
Results: For evaluation of psychometric properties (validity, reliability, sensitivity of change) of EDSS and MSFC,
120 relevant full-text publications were identified, 54 of them assessed the EDSS, 26 the MSFC and 40 included both
instruments. The EDSS has some documented weaknesses in reliability and sensitivity to change. The main limitations of
the MSFC are learning effects and the z-scores method used to calculate the total score. However, the methodological
criterion of validity applies sufficiently for both instruments.
For use in clinical studies, we found the EDSS to be preferred as a primary and secondary outcome measure in recent
studies (50 EDSS, 9 MSFC).
Conclusions: Recognizing their strengths and weaknesses, both EDSS and MSFC are suitable to detect the effectiveness
of clinical interventions and to monitor disease progression. Almost all publications identify the EDSS as the most widely
used tool to measure disease outcomes in clinical trials. Despite some limitations, both instruments are accepted as
endpoints and neither are discussed as surrogate parameters in identified publications. A great advantage of the EDSS is
its international acceptance (e.g. by EMA) as a primary endpoint in clinical trials and its broad use in trials, enabling
cross-study comparisons.
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Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system that mainly affects young
adults. The disease is characterized by the occurrence of
relapsing neurological deficits that affect different func-
tional systems of the central nervous system. The majority
of patients initially present with a relapsing remitting dis-
ease course (RRMS > 80%), however after 10 – 15 years
about 60% of these patients show a transition into a sec-
ondary progressive disease course (SPMS) that is charac-
terized by a gradual decline of neurological function. In
less than 15% of cases, the disease course is progressive
from the onset (primary progressive MS, PPMS) [1].
In recent decades, a number of instruments have been
developed that describe the clinical severity and the func-
tional deficits in multiple sclerosis. These instruments are
increasingly used as an endpoint in clinical trials to assess
the effectiveness of therapeutic interventions.
The most popular and widely used instrument is the
Expanded Disability Status Scale (EDSS) of Kurtzke [2].
The EDSS is a clinician-administered assessment scale
evaluating the functional systems of the central nervous
system. The EDSS is used to describe disease progres-
sion in patients with MS and to assess the effectiveness
of therapeutic interventions in clinical trials. It consists
of ordinal rating system ranging from 0 (normal neuro-
logical status) to 10 (death due to MS) in 0.5 increments
interval (when reaching EDSS 1). The lower scale values
of the EDSS measure impairments based on the neuro-
logical examination, while the upper range of the scale
(> EDSS 6) measures handicaps of patients with MS.
The determination of EDSS 4 – 6 is heavily dependent
on aspects of walking ability.
Another important instrument is the Multiple Sclerosis
Functional Composite (MSFC) [3], which was developed
by the MS Society’s Clinical Assessment Task Force [4] as
an additional clinical measure of MS disability progres-
sion. The primary goal for creating the MSFC was to im-
prove the standard measure of MS disability for clinical
trials and to develop a multidimensional metric of overall
MS clinical status [4]. The MSFC is a three-part perform-
ance scale for evaluating the degree of impairment in MS
patients. It includes the assessment of leg function by
moving a short walking distance (“Timed 25-Foot Walk”,
T25FT), the assessment of arm function using breadboard
test (“9-Hole Peg Test”, 9HPT) and an attention/concen-
tration test to assess cognitive functions (“Paced Auditory
Serial Addition test”, PASAT). An integrated MSFC score
is calculated using z-scores. There is an ongoing debate
about which dimensions to include in the MSFC (e.g. the
inclusion of a vision testing) as well as how the reference
population affect the standardized scoring (z-scores) of
the MSFC [5-13]. In recent years, the MSFC is increas-
ingly used in clinical trials.A number of other instruments are available to assess
MS: the Ambulation Index (AI) [14], the Scripps Neuro-
logical Rating Scale (SNRS) [15] and the Illness Severity
Scale (ISS) [16], the Guy’s Neurological Disability Scale
(GNDS) [17] and the Multiple Sclerosis Impairment
Scale (MSIS) [18]. Furthermore, the overall Functional
Independence Measure (FIM) [19] and the Cambridge
Multiple Sclerosis Basic Score (CAMBS) [20] are clinical
assessment instruments that could be used to assess MS
[21]. Specific instruments for measuring health-related
quality of life in MS patients are the Multiple Sclerosis
Quality of Life-54 (MSQOL-54) [22] and the Multiple
Sclerosis Quality of Life Inventory (MSQLI) [23]. Only a
few of these instruments meet the requirements of meth-
odological standards (e.g. validity, reliability, responsive-
ness), particularly for use in clinical trials. None of these
instruments is recognized to use in clinical trials without
any restrictions.
The aim of this study was to identify strengths and
weaknesses of EDSS and MSFC. We investigated to what
extent the psychometric properties of the two most
important instruments – EDSS and MSFC – meet the
methodological standards and what value they have in
clinical trials. Although different methodological charac-
teristics of the EDSS are the focus of many studies, a
summary and synthesis of the study results is missing. In
addition, the importance the MSFC is still a matter of
debate and a summary of its methodological characteris-
tics is also missing. We addressed this gap by conducting
a systematic literature review to specifically answer the
following questions:
 Are the instruments suitable to detect the efficacy
and/or effectiveness of clinical interventions and to
monitor the disease progress?
 Do the methodological properties of EDSS and
MSFC meet the required standards of objectivity,
reliability and validity as applied to instruments for
assessment of disease impact in MS?
 What is the evidence of the practicality and
sensitivity to change of these instruments?
 Which methodological shortcomings of EDSS and
MSFC must be considered in interpretation of
study results?
 Which minimally important difference (minimal
clinically important difference, MCID) is reported
for EDSS and MSFC?
Methods
The study was conducted in two phases. First, an explora-
tory electronic literature search was undertaken to (a)
develop and optimize a systematic search strategy and (b)
estimate the extent and quality of available studies. Then,
a systematic literature search was conducted using the
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(PubMed), ISI Web of Science, EMBASE, PsycINFO and
CINAHL & PSYNDEX were systematically searched.
Search terms were: Multiple Sclerosis + Expanded Disabil-
ity Status Scale OR EDSS (for EDSS) and Multiple Scler-
osis +Multiple Sclerosis Functional Composite OR MSFC
(for MSFC) (Table 1).
Overall, 3680 results were identified (4272 of the ini-
tially generated 8132 hits were excluded as duplicates);
the abstracts were reviewed by two independent scien-
tists and structured according to the following criteria:
1) Psychometric studies: validity, reliability, sensitivity
of change, head-to-head comparisons, further
developments of EDSS or MSFC and reviews.
2) Publications on clinical trials in which the EDSS
and/or the MSFC is used as outcome measure
or part of it.
3) Other types of studies, if these relate to the central
question (for example, review articles).
When the theme did not meet the research question,
the abstract was excluded. A total of 684 publications
were classified as relevant and ordered as full-text publi-
cations in electronic copy or selected in lending (psy-
chometric publications n = 295; papers on clinical studies
n = 364; reviews, summaries etc. n = 25).
In a further selection process the full-text psychomet-
ric papers (n = 295) were reviewed and subdivided into:
1) Studies that include information about the
psychometric properties of the investigated scores
(validity, reliability, sensitivity to change, and
head-to-head comparisons).
2) Studies that focus on a different instrument
than EDSS and/or MSFC (without acceptable
psychometric information about the EDSS or MSFC).
3) Studies that are not relevant to the central study
questions.
The categories 2 and 3 were excluded. Ultimately, 120
papers were identified as relevant methodological publica-
tions. Figure 1 gives an overview of the selection process.Table 1 Results of systematic literature research*
EDSS
MEDLINE (PubMed) (all limits) 1814
ISI Web of Science (limit language) 2358
EMBASE (all limits) 1890
PsycINFO & PSYNDEX (limits humans, adult) 1282
CINAHL (limit humans, adult) 504
*According to database limitations, the search was specified by additional search cr
French, Spanish).In addition, the publications on clinical trials were
reviewed. Furthermore, the public register of clinical trials
ClinicalTrials.gov by the U.S. National Institutes of Health
was systematically searched and an overview of relevant
clinical studies generated.
Results
We identified 120 publications with methodological con-
tent for EDSS and/or MSFC. Table 2 gives an overview
of scores distribution and period of publication.
Numerous relevant studies of EDSS were published
before 2000 [24-32]. The majority of the MSFC studies
as well as the head-to-head comparisons were published
between the years 2000 and 2009.
Development of EDSS and MSFC as endpoint in clinical trials
In the early clinical studies evaluating therapeutic inter-
ventions for MS, the effectiveness of treatment was ex-
clusively measured by reducing the number of relapses,
due to the importance of relapses for disease progression
[33-38]. However disease progression measured by EDSS
was introduced as a primary endpoint in 1996 when the
therapeutic effect of Interferon-beta 1a i.m. was evaluated.
Currently, progression of disability measured by EDSS is
the most important secondary endpoint in MS trials ad-
dressing RRMS patients and the most important primary
endpoint in all studies dealing with therapeutic interven-
tions in patient with a progressive disease course. Recent
studies usually also include the MSFC-score as an end-
point in clinical trials [39-41].
Therefore the current guidelines of the European
Medicines Agency (EMA) [42] recommend prevention
and delay of disability progression for SPMS and PPMS
studies and relapses, disease progression and the increase
in disability for studies on RRMS or SPMS (with superim-
posed relapses) as primary or secondary endpoints.
Psychometric properties of EDSS and MSFC
EDSS
Overall, we identified 54 full-text publications in which
the psychometric properties of the EDSS (without com-
parison to the MSFC) were examined. One of the studies
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Figure 1 Selection process of methodological publications for
EDSS and/or MSFC.
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reliability, 8 the sensitivity of change and 10 included
modifications of the EDSS, especially versions for self-
reporting. In addition, there is a simulation study on
power (overlaps are possible). (The 40 studies which
consider the MSFC as well are not listed here; for more
information see MSFC.)
Kurtzke himself did not test the psychometric properties
of EDSS. A series of studies on the properties and the
functional systems of the EDSS was conducted as aware-
ness of psychometric methods increased [24-29,32,43-45].
Most of the early studies concentrated on reliability. A
first study considering reliability, validity and sensitivity to
change is the work of Sharrack and colleagues [29]. ATable 2 Psychometric publications classified by score and
year
Score Year of publication
Up to 1999 2000-2009 Since 2010 Total
EDSS 29 19 6 54
MSFC* 3 19 4 26
EDSS +MSFC* ** 2 33 5 40
Head-to-head-
comparisons
- 11 1 12
Total 120
*Some studies deal only with parts of the MSFC (T25FW, 9HPT, PASAT).
**This includes although publications that examine other instruments besides
EDSS and MSFC.detailed study on the validity, reliability (inter-and intrara-
ter reliability), sensitivity to change, and floor and ceiling
effects on a sample of patients with MS is published from
Hobart and colleagues in 2002 [32].
Validity The validity of the EDSS has been established
in numerous studies: Amato and colleagues [31] certify a
good validity of the EDSS; Ebers [46] described the EDSS
as “well validated”. In early studies, the EDSS was corre-
lated with the Barthel Index (BI), the London Handicap
Scale (LHS), the Scripps Neurological Rating Scale (SNRS),
the Functional Independence Measure (FIM) [47] and phy-
sical function ability of the SF-36; strong to very strong
correlation could be shown [29,32,48], weaker results were
reported between the EDSS and the ambulation index (AI)
[17,49]. In addition, the EDSS correlated with neuro-
psychological impairment and brain changes measured by
MRI – with no or weak correlations [50]. Results of cor-
relations of EDSS with patient-reported outcomes were
heterogeneous, from moderate to no correlation.
In studies checking the validity of the MSFC, the EDSS
is often used as gold standard reference (see the validity
of the MSFC in the next section).
Reliability A criticism of several studies is the limited
reliability of EDSS measurements [24,25,27,44,51]. For
inter-rater reliability kappa values between 0.32 to 0.76
for the EDSS and between 0.23 to 0.58 for the individual
functional systems were reported [24,25,27,44,52]. The
intra-rater agreement is slightly higher than the inter-
rater, they both show greater variability for lower EDSS
scores (1.0-3.5) than for higher score values [27,53].
Different intervals of agreement (exact match, one step
(0.5 points), two steps (1.0 points), etc. on the EDSS
scale) affect the degree of reliability; studies that attest
good reproducibility to the EDSS allow higher deviations.
From a deviation of 3 steps on the EDSS scale (1.5 points)
almost all studies report good to perfect inter-rater
reliability.
Sensitivity to change In the literature review, the EDSS
was found somewhat sensitive to changes in disease pro-
gression [17,54]. Schwid and colleagues [55] compared
limitations of walking ability in MS patients, the EDSS
and Ambulation Index and found them to be less sensi-
tive to change than the Dmax (the maximum distance
that a person can go) and T8 (time to walk 8 m). Simi-
larly, Vaney and colleagues [56] reported lesser changes
in EDSS than in the Rivermead Mobility Index (RMI),
the AI and the 10 m walking time test. Hohol and
colleagues [53] reported a lower sensitivity to change in
EDSS compared with Disease Steps. In turn, Koziol and
colleagues [57] observed in a clinical study that the
EDSS and the Scripps Neurological Rating Scale could
Meyer-Moock et al. BMC Neurology 2014, 14:58 Page 5 of 10
http://www.biomedcentral.com/1471-2377/14/58reflect improvements in the cladribine group and deteri-
orations in the placebo group appropriately.
Moreover, some studies showed that the rates of
change varied depending on the initial value. Greater
rates of change were observed for minor severity of
disease, but from an EDSS score of 6, the EDSS showed
very little change in sensitivity [58]. Ravnborg and
colleagues [59] reported higher annual rates of change
(worsening health) at low EDSS baseline.
Feasibility, scale- and distribution properties The EDSS
shows a bimodal frequency distribution in a number of
studies [29,30,54,57] with only a few values in the
central region and two peaks around the values 3 and 6
[31,53,59].
In numerous studies the unequal interval distances
between the EDSS have been criticized, [31,54,60], par-
ticularly in the context of clinical trials. This leads to
different meanings of change depending on the position
on the scale: a difference between the values 1.0 and 2.0
has a different relevance as between 6.0 and 7.0 [61].
Amato and Ponziani [31] as well as Drulovic and col-
leagues [62] criticized that the use of parametric statistical
methods is not possible. The EDSS is also not suitable for
use in economic analyses [63]. The non-linearity was
demonstrated in studies comparing the EDSS with the
health-related quality of life [22,64].
As reported in the literature, the lower scale values
(0-4.0) are influenced by impairments detected by the
neurological exam of eight functional systems, while
the values above 4.0 are mainly based on the walking
ability, and values above 6 mainly on patients handi-
caps [56,62].
Interpretation and comparability A clear recommen-
dation how to interpret changes in EDSS-values cannot
be found in the literature. Noseworthy et al. [24] recom-
mend a progression of 1.0 as a meaningful change in
clinical trials. Similarly, Healy and colleagues [65] rec-
ommended using a continuing progression by one unit
on the scale for at least 6 or 12 months. On the other
hand, Francis et al. [25] suggested a change of 1.5 points
to be more appropriate. For patients with an EDSS of
5.5 or higher at inclusion in the study, progression by
0.5 was deemed sufficient, since changes in this range of
the scale are easily perceptible [66].
The guidelines of the European Medicines Agency
(EMA) [42] suggest that an average change from base-
line is not an adequate efficacy parameter. Instead, they
recommend defining treatment success or treatment
failure of either reaching a certain EDSS score or a sus-
tained change in sufficient volume. A separate consider-
ation of the lower and upper value range of the EDSS is
recommended: 1 point on the EDSS scale with a baselineEDSS score less than or equal to 5.5 and 0.5 points in an
EDSS score over 5.5.
A commonly recognized benefit of the EDSS is its
good comparability of results from different studies
[31,42,63]. The EDSS is fairly robust for measurements
over a long period [46,62].
MSFC
Overall, we identified 66 full-text publications in which
the psychometric properties of the MSFC are reported.
Of these, 10 were reviews or summaries, 14 examined
the validity, 18 the sensitivity to change and 4 the reli-
ability. Seven publications included modifications to the
MSFC. A total of 40 publications also contain infor-
mation on the EDSS with two publications assessing the
superiority of the MSFC over the EDSS [3,4] (overlaps
are possible).
Validity MSFC has been shown to correlate with other
indicators of disease in MS, including the EDSS, MRI
measures (although correlation here is weak) [67,68], pa-
tient reported health [69-71] and employment [3,5,72-74].
The predictive validity of MSFC has also been shown for
EDSS, brain atrophy, SPMS disease and self-reported
health [74].
The EDSS is used most often to test the validity of the
MSFC – studies found strong correlations between the
two scores, ranging from -0.41 to -0.83 [3,71,75-77]. The
PASAT is the weakest correlate [3]. Kalkers and colle-
gues [78] found that while overall MSFC scores distin-
guished across MS disabilities, the PASAT could not
distinguish as well. In fact, Brochet et al. [67] found no
correlation between PASAT and EDSS. Rudick and
collogues [9] found that MSFC progression seem to be
driven by one component of the MSFC, the Timed
25-Foot Walk (T25FWT).
Correlation with MRI measures [67,68] and patient
reported outcomes [69-71] were inconsistent, showing
moderate to no correlations. For example, MSFC was
correlated with the physical component of the SF-36
scale and the sickness impact profile, but not with the
mental component of the SF-36 [70]. Change in MSFC
score also is shown to have a very weak correlation with
change in SF-36 score [79].
Reliability The source publication [4] found MSFC
reliability to be high (intra-rater ICC = 0.98, inter-rater
ICC = 0.96). Inter-rater and intra-rater reliability were
shown to be high for MSFC overall score as well as its
component measures. The intraclass correlation (ICCs)
were above 0.8 across studies [4,52,78,80]. Schwid and
colleges [81] found that MSFC scores varied over meas-
urement periods (over 5 days) but all within 20% change
in raw scores.
Table 3 EDSS and MSFC as primary or secondary outcome
in relevant clinical trials*
Start of study
1990 - 2000 2000 – today Total
EDSS 13 37 50
Primary outcome 10 17 27
Secondary outcome 3 20 23
MSFC - 9 9
Primary outcome - 1 1
Secondary outcome - 8 8
*Not taken into account is that the EDSS is in addition to the primary outcome
used as secondary outcome. In this overview, only a classification in the “higher”
endpoint occurs.
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strated practice effects, meaning that as participants
learn about the test, their scores improve [4,52,80,82,83].
This is a general problem of all studies that follow
patients over time. The MSFC manual suggests adminis-
tering the PASAT at least three times prior to baseline
measurement to address this practice effect as there is
some evidence that practice effects stabilized by the
4th observation [73,75]. However, some evidence point
to practice effect persisting beyond fourth testing re-
peats [83].
Some studies did not detect notable practice effects
[71,84,85]. However, due to potential artifacts that may
lead to overestimations of improvement in MSFC scores,
precautions should be taken during data collection.
Sensitivity to change In the source database [4], MSFC
was found to significantly decline from baseline (z = -0.14)
to 2 years (z = -0.14) for patients in placebo groups of
clinical trials. They also found patients with MSFC deteri-
orating by at least one standard deviation to have an odds
ratio of 2.1 for sustained EDSS deterioration [3,4].
Some studies indicate the MSFC to be more sensitive
than EDSS to detecting changes in disease [71,84-86].
However, due to missing dimensions (e.g visual function)
there is also evidence that the MSFC is not more sensitive
than the EDSS [73,77]. Others found the PASAT does not
reflect disease progression in certain MS populations
[11 for PPMS].
Feasibility Fischer et al. [4] found that it took 15 minutes
for trained personnel to administer the MSFC to patients
(using a small sample of 10 patients). The PASAT, how-
ever, is notoriously disliked by patients [73]. From our
review, some studies found patients not willing to undergo
the PASAT [76,87].
Interpretability A major drawback of the MSFC is its
interpretability, especially in the scoring mechanism.
Although choice of reference population does not affect
statistical significance [4], it does change the value of the
z-scores, making cross-trial comparison problematic.
Some studies examined reference population choice on
MSFC scores [10,78,88] and found the question of refer-
ence population problematic.
A further objection to z-score interpretability is its
abstractness from clinically meaningful values. A solu-
tion involves using clinically relevant cut-offs in the
raw scores of MSFC dimensions as opposed to z-scores.
Bosma et al. [82] found optimal cutoff values to be 20%
change for the T25FW and 20% for the 9HPT but could
not determine a relevant cutoff for PASAT. Hoogervorst
et al. [69] established that 20% change in all three MSFC
measures were meaningful to patient’s own perception ofhealth (using the GNDS as a reference measure). Similarly,
other studies found the 20% change in T25FW [89,90]
and 9HPT [90] reflect disease status in MS patients.
Rudick et al. [9] further found, using data from the
AFFRIM and SENTINEL trials, that a 15 or 20% change,
sustained for 3 months, seems to be an adequate way
to quantify the MSFC dimensions. However, others
found the 20% not sufficient to detect neurological
worsening [81].
Use of EDSS and MSFC in Clinical Trials
In addition to the review, a systematic search in the pub-
lic register of clinical trials ClinicalTrials.gov by the U.S.
National Institutes of Health was conducted to identify
relevant clinical trials for MS. Under the topic multiple
sclerosis (search terms) 904 studies were identified. In a
second step, clinical phase III or IV studies on interferon
beta-1b, interferon beta-1a, glatiramer acetate, fingoli-
mod, natalizumab, mitoxantrone and cyclophosphamide
as well as – due to their current importance – studies
on laquinimod, teriflunomide, BG-12 and alemtuzumab
were extracted. Finally, 66 clinical phase III or IV studies
to a relevant agent of MS therapy could be identified. In
50 of those studies EDSS and/or MSFC were used as pri-
mary and/or secondary outcome measurement method
(in 15 studies EDSS/MSFC were not reported, in 1 study
EDSS was named as a tertiary endpoint). In 9 of the 50
relevant studies the MSFC was used in addition to
the EDSS, but there is no study that used only the
MSFC (Table 3). It was found that the EDSS has been
used preferentially as primary and secondary outcome
measurement.
Discussion
This study examined the extent to which the psycho-
metric properties of the most important instruments
to assess disease progression in MS – EDSS and
MSFC – meet the methodological standards and what
value they have as outcome measures in clinical trials.
Meyer-Moock et al. BMC Neurology 2014, 14:58 Page 7 of 10
http://www.biomedcentral.com/1471-2377/14/58In a systematic literature review of 120 relevant full-
text publications, we found that while the EDSS is the
most widely used instrument in clinical trials assessing
the effectiveness of therapeutic interventions, the MSFC
is becoming increasingly important.
Single methodological characteristics of the two in-
struments have been investigated in numerous studies.
The EDSS has some documented weaknesses in relia-
bility and sensitivity to change. Although the MSFC was
developed rigorously, its weaknesses include interpreting
the z-scores (which are used to calculate the summary
score from the three components), the learning effects of
the PASAT, low acceptance by patients and lack of a visual
dimension. However, the MSFC has better sensitivity
and reliability compared to EDSS. The methodological
quality criterion of validity is sufficiently met by both
instruments.
Despite the criticisms, in particular the EDSS could be
classified as an important endpoint. In neither publica-
tion, the EDSS (or MSFC) are discussed as a surrogate par-
ameter (in contrast to MRI measurements). Cohen et al.
[73] emphasized in their review of clinical outcome para-
meters, the general acceptance of the EDSS as an endpoint
by different authorities. In contrast, the MSFC is usually
used as a secondary endpoint.
The importance of the instruments is also reflected in
our evaluation of clinical trials: in 50 of 66 identified
relevant phase-III and phase-IV studies, disease progression
as measured by EDSS was used as primary (27 studies) or
secondary outcome (23 studies). The MSFC was used in
eight studies as a secondary endpoint and only one study
as a primary endpoint.
In summary, both instruments are acceptable outcome
criteria to assess the effectiveness of clinical interven-
tions and to monitor disease progression. When using
the EDSS, its limited inter-and intra-rater reliability
should be considered. All possibilities to increase reli-
ability should be used, including training of investi-
gators, assessment by the same doctor/neurologist
during the study, specified times of detection, stan-
dardized protocols for neurological examination and a
precise definition of all requirements. When using the
MSFC, the learning effects of the PASAT and 9HPT
should be considered and controlled (e.g. using con-
trol groups).
Concerning the natural history of MS, Weinshenker
and colleagues [1] observed an average change of 0.5
points on the EDSS scale in a year. A clear recommen-
dation on interpreting changes in EDSS and MSFC
values does not yet exist. EDSS changes by 1.0 points
from a baseline EDSS less than or equal to 5.5 and 0.5
points over a baseline 5.5 are commonly recognized as a
clinically increase in disability. However, it is now under-
stood that it is more accurate to define disability changeas a sustained change for 12 weeks or, even more reli-
ably, for 24 weeks.
For the MSFC, changes by 20% in the individual com-
ponents are considered to be clinically relevant. How-
ever, it is difficult for a clinician to understand what a
20% change in MSFC subscores is while a significant
EDSS change is more intuitively understood.
Overall, the literature reveals that the EDSS is the most
widely used and best-known instrument to assess disease
progression in MS. The advantages and disadvantages of
EDSS and MSFC have been investigated frequently. The
great advantage of the EDSS is its international acceptance
(including the EMA) as a primary endpoint in clinical
trials. Because it is so commonly used, studies that use the
EDSS can easily compare results to other findings. Follow-
ing the current literature, we can conclude that the im-
portance of the EDSS will be unabated in future. Major
changes of the EDSS are not recommended, as not to
jeopardize its advantage.
In addition, the use of other measurements as clinical
trial endpoints (e.g. the MSFC) is recommended to pro-
vide information on dimensions no covered in the EDSS,
such as upper limb function or cognitive skills.Conclusions
The assessment instruments we examined, EDSS and
MSFC, both are frequently and internationally used in
clinical studies – despite their well know methodological
limitations. They are suitable to detect patient-relevant
endpoints in MS with reasonable validity in spite of
some methodological concerns.Consent
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